FDA Accepts Lonvo-z BLA for Priority Review
FDA accepted Intellia Therapeutics’ biologics license application for lonvoguran ziclumeran, or lonvo-z, granted Priority Review and set a March 10, 2027 target action date. FDA advised the company that it is not currently planning…
